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Abstract
Background: While Brazil has had a long-standing policy of free access to antiretroviral therapy (ART) for all in need,
the epidemiological impact of ART on human immunodeficiency virus (HIV) RNA suppression in this middle-income
country has not been well evaluated. We estimate first-line ART effectiveness in a large Brazilian cohort and examine
the socio-demographic, behavioral, clinical and structural factors associated with virologic suppression.
Methods: Virologic suppression on first-line ART at 6, 12, and 24 months from start of ART was defined as having a
viral load measurement ≤400 copies/mL without drug class modification and/or discontinuation. Drug class modification
and/or discontinuation were defined based on the class of a particular drug. Quasi-Poisson regression was used
to quantify the association of factors with virologic suppression.
Results: From January 2000 through June 2010, 1311 patients started first-line ART; 987 (75%) patients used
NNRTI-based regimens. Virologic suppression was achieved by 77%, 76% and 68% of patients at 6, 12 and
24 months, respectively. Factors associated with virologic suppression at 12 months were: >8 years of formal
education (compared to <4 years, risk ratio (RR) 1.13, 95% confidence interval (95% CI) 1.03-1.24), starting ART
in 2005-2010 (compared to 2000-2004, RR 1.25 95% CI 1.15-1.35), and clinical trial participation (compared to
no participation, RR 1.08 95% CI 1.01-1.16). Also at 12 months, women showed less virologic suppression
compared to heterosexual men (RR 0.90 95% CI 0.82-0.99). For the 24-month endpoint, in addition to higher
education, starting ART in the later period, and clinical trial participation, older age and an NNRTI-based
regimen were also independently associated with virologic suppression.
Conclusions: Our results show that in Brazil, a middle-income country with free access to treatment, over
three-quarters of patients receiving routine care reached virologic suppression on first-line ART by the end of
the first year. Higher education, more recent ART initiation and clinical trial participation were associated with
improved outcomes both for the 12-month and the 24-month endpoints, suggesting that further studies are
needed to understand what aspects relating to these factors lead to higher virologic suppression.
Keywords: HIV/AIDS, Antiretroviral treatment, Effectiveness, Cohort study, Rio de Janeiro, Brazil
Background
Since the beginning of the HIV/AIDS epidemic, Brazil’s
response has been both timely and inclusive, addressing
prevention as well as treatment. A noteworthy moment
was the decision to provide highly active antiretroviral
therapy (ART) for all patients in need in 1996. With over
15 years of universal access to ART and almost 300,000
patients receiving ART, Brazil’s HIV treatment program
stands alone in its universal coverage of all in need com-
pared to other middle-income or resource-limited coun-
tries [1]. Despite the enormous publicity it has received,
evaluations of Brazil’s HIV treatment program are limited.
Studies have indicated that morbidity and mortality from
HIV infection has fallen since the introduction of ART
[2-4]. However, studies evaluating the impact of ART in
suppressing HIV viral load, i.e. its effectiveness within the
routine care provided through the public health system
(the Unified Health System) of Brazil are scarce.
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randomized clinical trials usually conducted in selected
populations which frequently exclude participants with
concurrent opportunistic diseases, substance abuse and/
or psychiatric comorbidities [5]. As such, results from
clinical trials are often not generalizable to all treated in-
dividuals who might be part of a clinical cohort or to
longer-term outcomes [6]. Understanding ART effective-
ness within the routine care setting is crucial to guide
the evolution of the Brazilian HIV Treatment program.
In this study, we evaluated first-line ART effectiveness
for patients starting therapy from 2000 to 2010, as well
as the factors that correlate with virologic suppression in
a large urban cohort in Rio de Janeiro, Brazil.
Methods
The IPEC clinical cohort
This study was conducted at the Evandro Chagas Clinical
Research Institute, Oswaldo Cruz Foundation (IPEC/
FIOCRUZ), one of the largest infectious disease research
centers in Brazil, where care has been provided to HIV/
AIDS patients since the beginning of the AIDS epidemic
in Brazil in 1986. An observational, longitudinal, clinical
database is maintained on patients receiving primary and
specialized outpatient and inpatient HIV care at the clinic;
it includes socio-demographic, behavioral, clinical and
therapeutic information. Details of the HIV/AIDS clinical
cohort can be found elsewhere [7,8]. The IPEC Institu-
tional Review Board reviewed and approved this study.
Study population and definitions
All patients who started first-line ART between January 1,
2000 and June 30, 2010 were included and follow-up in-
formation included data through September 30, 2011.
Though combination ART became available in mid-1996,
we specifically excluded 1996-1999 because it was a period
characterized by non-standardized combinations as well
as continued exposure to mono or dual therapy, which
were kept in the prior to 2000 guidelines as alternative
first-line regimens. ART was defined as two nucleoside
reverse transcriptase inhibitors (NRTI) in combination
with one non-nucleoside reverse transcriptase inhibitor
(NNRTI) or one protease inhibitor (PI). Drug class modifi-
cation and/or discontinuation were defined based on the
class of a particular drug. A patient who started a first-line
NNRTI-based regimen, for example, was assumed to have
modified and/or discontinued the regimen if it was chan-
ged to a PI-based regimen or if the NNRTI was discontin-
ued. NRTI modifications and/or discontinuations were
not considered since these could be due to reasons unre-
lated to a drug-class failure. For the years 2000-2010, ART
guidelines were consistent regarding first-line ART with
NNRTI-based regimens cited as preferred and PI-based
regimens as alternative options.
First-line ART effectiveness
First-line ART effectiveness was defined as having HIV
viral load ≤400 copies/mL and no drug class modifica-
tion and/or discontinuation. Deaths from AIDS-related
causes were considered as failures. Because the limit of
detection of viral load assays used throughout the study
period varied from ≤400 copies/mL to ≤50 copies/mL,
we used the ≤400 copies/mL threshold for the entire
study period for consistency.
We examined virologic outcomes at 6, 12, and 24 months
from first-line ART initiation. Window periods were de-
fined for each time point as 5-9 months, 9-15 months, and
21-27 months, respectively. Within each window, the viral
load measurement occurring closest to the target time
point (either before or after) was chosen. Drug class modi-
fication and/or discontinuations were evaluated for the en-
tire period from the start of first-line ART until the upper
limit of each window period.
Missing data
The IPEC Cohort has a validated algorithm for identifi-
cation of deaths which has been previously described
[8,9]. In addition, since IPEC provides outpatient and in-
patient care, as well as a multidisciplinary team including
a cadre of clinical specialties coupled with pharmaceutical
care, the rate of loss-to-follow-up is low (4.1/100 person-
years). Absence of laboratory measurements is most fre-
quently a result of insufficient infrastructure to support
the CD4/viral load monitoring needed for all patients on
ART. As such, we evaluated the impact of missing viral
load measurements on first-line ART effectiveness by
examining both best and worst-case scenarios. In the best
case scenario, missing viral load data were assumed as sup-
pression. Alternatively, in the worst-case scenario, missing
viral loads were imputed as failures.
Immunologic response
We examined CD4 counts 6, 12, and 24 months from
ART initiation. Window periods were, as for viral loads,
defined for each time point as 5-9 months, 9-15 months,
and 21-27 months. Within each window, the CD4 count
occurring closest to the target time point (either before
or after) was chosen.
Statistical analyses
First-line ART effectiveness was calculated as the prob-
ability (95% CI) of viral suppression at 6, 12 and 24 months
after ART initiation. The impact of socio-demographic,
behavioral, clinical and structural factors on virologic
suppression at 12 and 24 months was estimated using
a quasi-Poisson regression model; this corrected for
variance estimation and allowed for the estimation of rela-
tive risks. We chose the use of quasi-Poisson models since
the data showed overdispersion (i.e. the variance was
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sumption of the Poisson model which assumes that the
variance is equal to the mean) and because log-binomial
regression models did not converge. The final model in-
cluded variables found to be significant at a threshold
p-value of 0.05, as well as factors known to be clinically
relevant or that were shown to modify the effect of a covar-
iate in the adjusted model. We also examined the impact of
missing viral load measurements on the final model by re-
estimating the parameters while assuming the worst-case
and best-case scenarios. R software version 2.15.2 (www.r-
project.org) was used for all statistical analyses.
Results
Study population
From January 2000 through June 2010, 1,311 patients
started first-line ART; 40% were ≥40 years old (Table 1).
Among men, men who have sex with men (MSM) pre-
dominated as the HIV risk exposure category; 9.8% of
the study population reported injection drug use (IDU)
or other modes of HIV risk exposure. Half of the cohort
had over 8 years of education. Sixty-four percent of the
patients had three years or less since their first posi-
tive HIV test; 494 (37.7%) had a pre-treatment CD4
count ≤200 cells/μL (overall median 222/μL, IQR:105-
322 cells/μL), and 466 (35.5%) had a pre-treatment viral
load >100,000 copies/mL. The majority of patients started
a first-line NNRTI-based regimen (987, 75.3%). Seventy
percent of patients started their first-line regimens in the
calendar period 2005-2010. Just over one-third of patients
started first-line ART within a clinical trial conducted
at IPEC.
Among the 987 patients who started an NNRTI-based
regimen, efavirenz (EFV) was used by 93.3% (921/987); the
most frequent EFV-based combination was zidovudine
(AZT)+lamivudine (3TC)+EFV (590/921, 64.1%), followed
by tenofovir (TDF)+3TC+EFV or TDF+emtricitabine
(FTC)+EFV (252/921, 27.4%). Among the 324 patients
who started a PI-containing regimen, the majority used a
boosted PI (197/324, 60.8%). The most frequent boosted
PI was ritonavir-boosted lopinavir LPV/r (93/197, 47.2%)
followed by ritonavir-boosted atazanavir ATV/r (62/197,
31.4%). Among those who started a non-boosted PI regi-
men (127/324, 39.2%), 65.4% (83/127) started with ATV.
The frequency of boosted PI prescriptions was 47.8%
(54/113) for the calendar year 2000-04 and 67.7%
(143/211) for 2005-10.
First-line ART effectiveness
Overall first-line ART effectiveness, inclusive only of those
with viral load data, was 76.9%, 76.1% and 67.9% at 6, 12
and 24 months (Table 2, top section). When assuming
the best-case scenario including all patients, ART ef-
fectiveness increased to 82.8%, 80.8% and 77.0% at 6, 12
and 24 months. Inclusive of all patients, the worse-case
scenario produced ART effectiveness rates of 57.5%, 61.2%
and 48.6% at 6, 12 and 24 months. First-line ART effect-
iveness at each time point was consistently higher for
those using an NNRTI-based regimen compared to a PI-
based regimen (Table 2, middle section). Increased effect-
iveness was also observed for those who started first-line
ART in 2005-2010 compared to those who started in
2000-2004 (Table 2, bottom section).
CD4 counts
Median CD4 counts for the entire cohort significantly
increased with the progression of the time points evalu-
ated (Figure 1). At baseline, the median CD4 count was
221/μL whereas at 6, 12 and 24 months, it was 338/μL,
375/μL and 448/μL. These improvements correspond to
a median CD4 count increase from baseline of 107/μL,
151/μL and 242/μL at 6, 12, and 24 months.
Factors associated with virologic suppression
In the adjusted model for the 12-month endpoint, gen-
der/risk category, education, calendar year of ART initi-
ation and participation in a clinical trial all remained
independently associated with virologic suppression
(Table 3). Compared to heterosexual men, women were
less likely to be virologically suppressed (RR 0.90 95% CI
0.82-0.99). Having over eight years of formal education
resulted in improved virologic suppression (RR 1.13 95%
CI 1.03-1.24), compared to less than four years of formal
education. Increased virologic suppression was also asso-
ciated with starting ART in 2005-2010 (RR 1.25 95%
CI 1.15-1.35) compared to starting in 2000-2004. Par-
ticipation in a clinical trial versus not was associated
with increased virologic suppression (RR 1.08 95% CI
1.01-1.16).
In the adjusted model for the 24-month endpoint, age,
gender/risk category, education, type of ART regimen,
calendar year of ART initiation, and clinical trial partici-
pation remained independently associated with virologic
suppression (Table 3). Virologic suppression was associ-
ated with older age (RR for ≥40 years old 1.12 95% CI
1.00-1.26, compared to<30 years old), and there was a
trend toward greater virologic suppression among MSM
compared to heterosexual men (RR 1.11 95% CI 0.98-
1.27). Again, women compared to heterosexual men
were less likely to be virologically suppressed, although
this estimate did not reach statistical significance. Viro-
logic suppression remained associated with first-line
NNTRI-based regimen (RR 1.17 95% CI 1.05-1.31, com-
pared to PI-based regimen), calendar year 2005-10 (RR
1.14 95% CI 1.03-1.27, compared to 2000-2004), and
participation in a clinical trial (RR 1.12 95% CI 1.02-
1.23).
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adjusted models (Table 4) showed that the direction of
the association of each variable with the 12-month and
the 24-month outcomes remained the same for both the
best case and worst case scenarios.
Discussion
In this large cohort study of HIV-infected patients in Rio
de Janeiro, Brazil, we estimated ART effectiveness for pa-
tients cared for between 2000 and 2010. We found that
ART effectiveness at 6 months was 77% among patients
with viral load results and no drug class modification and/
or discontinuation. Using an intent-to-continue-treatment
approach, that is, a less stringent criterion compared to
that of the present study, the ART-CC cohort reported
an estimate of 76% of undetectable viral load 6 months
after ART initiation [10]. For the 12-month time point,
our estimate of 61% for ART effectiveness when as-
suming missing data equals failure is consistent with
that reported in a systematic review of clinical trials
and cohort studies that employed the same approach
to evaluating first-line ART efficacy (57-66% [11-13]).
In line with our results, Barth et al., in a study con-
ducted in rural South Africa, found 55% effectiveness
using the same intent-to-treat approach [14]. It is import-
ant to consider the calendar period, the stringency of
study definitions and the availability of one pill once-daily
regimens, all factors that could partially explain diverging
suppression rates in other cohort studies when compared
to our findings [5,6,10,11,13-23].
We showed in a stratified analysis that ART effective-
ness was higher for NNRTI-based regimens. These
Table 1 Baseline socio-demographic, behavioral, clinical and
structural characteristics at first-line antiretroviral therapy
(ART) initiation (IPEC Clinical Cohort, 2000 to 2010)
Total 1311
Age
Mean (SD) 37.1 (9.9)
< 30 355 (27.1)
30-39 446 (34.0)
≥ 40 510 (38.9)
Race
Non-white 621 (47.4)
White 690 (52.6)
Gender/Risk category
a
Women 432 (33.0)
Heterosexual men 327 (24.9)
MSM 423 (32.3)
IDU/Other 129 (9.8)
Years of formal education
< 4 277 (21.1)
4-8 380 (29.0)
> 8 654 (49.9)
Years since HIV+ test
<= 3 836 (63.8)
> 3 475 (36.2)
Pre-treatment CD4 count/μL
b
Mean (SD) 233 (184)
<= 200 494 (37.7)
201-350 392 (29.9)
> 350 208 (15.9)
Missing 217 (16.6)
Pre-treatment HIV viral load copies/mL
c
<= 100000 532 (40.6)
> 100000 466 (35.5)
Missing 313 (23.9)
Concurrent AIDS defining illness
d
No 1013 (77.3)
Yes 298 (22.7)
Hepatitis B/C co-infection
e
No 1270 (96.9)
Yes 41 (3.1)
ART regimen
f
PI-based 324 (24.7)
NNRTI-based 987 (75.3)
Calendar year of ART initiation
2000-2004 392 (29.9)
2005-2009 919 (70.1)
Table 1 Baseline socio-demographic, behavioral, clinical and
structural characteristics at first-line antiretroviral therapy
(ART) initiation (IPEC Clinical Cohort, 2000 to 2010)
(Continued)
Started ART in clinical trial
No 856 (65.3)
Yes 455 (34.7)
SD: standard deviation, HIV: human immunodeficiency virus, PI: protease
inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
aGender and reported mode of HIV exposure were categorized jointly into
women, men who have sex with men (MSM), heterosexual men, and injection
drug users (IDU, men and women) and other reported modes of HIV exposure
(men and women). Individuals reporting both injection drug use and other
modes of HIV exposure were categorized as IDU.
bMeasurement closest to the date of start of ART up to 30 days after.
cMeasurement closest to the date of start of ART up to 7 days after.
dDefined as the presence of any Centers for Disease Control and Prevention
(CDC) 1993 disease from 90 days prior to up to 30 days after start of ART.
eChronic Hepatitis B infection was defined as persistence of a positive HBsAg
for more than six months without a subsequent negative HBsAg; chronic
Hepatitis C infection was defined as a confirmed positive anti-HCV detected at
least six months from the first test.
fPatients starting Integrase inhibitor-based regimens were too few and thus
excluded (7 individuals with start of ART in 2010).
Unless otherwise stated, number (percentages) are shown.
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studies that demonstrate greater effectiveness of NNRTI-
based regimens, in particular, of efavirenz-based regimens
[11,19,24]. In the adjusted analysis, however, the NNRTI-
based regimen was found to be independently associated
with virologic suppression solely at the 24-month end-
point; as such, when other factors were taken into account
the regimens were not significantly different. LPV/r
was the most frequently prescribed PI, as recommended
by the Brazilian HIV Treatment Guidelines, which may
explain the poorer outcomes observed with PI-based
regimens, as opposed to the comparable effectiveness
shown in AIDS Clinical Trials Group (ACTG5202), when
boosted atazanavir was the PI comparator [25]. Of note,
39% of the patients in our cohort who started a PI-based
regimen started on a non-boosted PI, of which 65% were
Figure 1 Box plot of CD4 count distribution at baseline and 6, 12, and 24 months after antiretroviral therapy initiation. Pair-wise
comparisons of baseline measurement with 6-, 12-, and 24-month time points indicate statistically significant differences (Wilcoxon paired test).
Table 2 Effectiveness of first-line antiretroviral therapy at 6, 12, and 24 months from start of antiretroviral therapy
(ART) stratified by regimen and calendar year
6 months 12 months 24 months
Overall N (%) N (%) N (%)
For patients with HIV VL 754/980 (76.9) 802/1054 (76.1) 637/938 (67.9)
Best-case scenario
a 1085/1311 (82.8) 1059/1311 (80.8) 1010/1311 (77.0)
Worst-case scenario
b 754/1311 (57.5) 802/1311 (61.2) 637/1311 (48.6)
Stratified by type of ART regimen
NNRTI-based
For patients with HIV VL 583/740 (78.8) 603/784 (76.9) 503/711 (70.7)
Best-case scenario 830/987 (84.1) 806/987 (81.7) 779/987 (78.9)
Worst-case scenario 583/987 (59.1) 603/987 (61.1) 503/987 (51.0)
PI-based
For patients with HIV VL 171/240 (71.3) 199/270 (73.7) 134/227 (59.0)
Best-case scenario 255/324 (78.7) 253/324 (78.1) 231/324 (71.3)
Worst-case scenario 171/324 (52.8) 199/324 (61.4) 134/324 (41.4)
Stratified by calendar year of ART initiation
2000-2004
For patients with HIV VL 157/252 (62.3) 188/297 (63.3) 171/287 (59.6)
Best-case scenario 297/392 (75.8) 283/392 (72.2) 276/392 (70.4)
Worst-case scenario 157/392 (40.1) 188/392 (48.0) 171/392 (43.6)
2005-2010
For patients with HIV VL 597/728 (82.0) 614/757 (81.1) 466/651 (71.6)
Best-case scenario 788/919 (85.7) 776/919 (84.4) 734/919 (79.9)
Worst-case scenario 597/919 (65.0) 614/919 (66.8) 466/919 (50.7)
HIV: human immunodeficiency virus, VL: viral load, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
aBest-case scenario assumes missing viral load data as suppression.
bWorst-case scenario assumes missing viral loads data as failures.
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at 12 and 24 months (IPEC cohort, 2000 to 2010)
12 months 24 months
Unadjusted Adjusted Unadjusted Adjusted
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Age
< 30 Ref. Ref. Ref.
30-39 0.99 (0.91, 1.08) 1.05 (0.93, 1.18) 1.06 (0.94, 1.19)
>=40 1.04 (0.95, 1.13) 1.09 (0.98, 1.22) 1.12 (1.00, 1.26)
Race
Non-white Ref. Ref.
White 1.07 (1.00, 1.14) 1.05 (0.97, 1.15)
Gender/Risk category
a
Women 0.89 (0.82, 0.98) 0.90 (0.82, 0.99) 0.92 (0.82, 1.03) 0.94 (0.84, 1.06)
Heterosexual men Ref. Ref. Ref. Ref.
MSM 1.05 (0.97, 1.15) 1.02 (0.93, 1.12) 1.11 (0.99, 1.25) 1.11 (0.98, 1.25)
IDU/Other 1.02 (0.90, 1.16) 1.02 (0.89, 1.16) 0.93 (0.78, 1.11) 0.95 (0.79, 1.13)
Education
< 4 years Ref. Ref. Ref. Ref.
4-8 years 1.06 (0.96, 1.17) 1.07 (0.96, 1.18) 1.12 (0.98, 1.28) 1.13 (0.99, 1.29)
> 8 years 1.16 (1.06, 1.27) 1.13 (1.03, 1.24) 1.17 (1.04, 1.32) 1.14 (1.00, 1.29)
Years since HIV+ test
<= 3 Ref. Ref.
> 3 0.97 (0.90, 1.04) 0.94 (0.86, 1.03)
Baseline CD4 cell count
b
<= 200 Ref. Ref.
201-350 1.05 (0.97, 1.14) 1.01 (0.91, 1.12)
> 350 1.09 (0.99, 1.20) 1.11 (0.97, 1.26)
Missing 0.92 (0.83, 1.03) 1.01 (0.88, 1.15)
Baseline HIV viral load
c
<= 100000 Ref. Ref.
> 100000 1.00 (0.93, 1.08) 1.03 (0.93, 1.14)
Missing 0.95 (0.87, 1.04) 0.99 (0.88, 1.11)
Concurrent ADI
d
No Ref. Ref.
Yes 1.06 (0.98, 1.16) 1.06 (0.95, 1.18)
Hepatitis B/C co-infection
e
No Ref. Ref.
Yes 1.16 (0.95, 1.43) 1.07 (0.83, 1.39)
Initial ART regimen
f
PI-based Ref. Ref. Ref.
NNRTI-based 1.04 (0.96, 1.13) 1.20 (1.08, 1.34) 1.17 (1.05, 1.31)
Calendar year of ART initiation
2005-2010 1.28 (1.18, 1.39) 1.25 (1.15, 1.35) 1.20 (1.09, 1.33) 1.14 (1.03, 1.27)
2000-2004 Ref. Ref. Ref. Ref.
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cluding non-boosted PIs have poorer outcomes compared
to other ART strategies [26]. The ACTG A5175 PEARLS
trial, which was conducted in both high-income and low-
middle-income settings, found non-boosted atazanavir to
be inferior to efavirenz-based regimens [27]. Thus, the use
of non-boosted PI-based regimens could partially explain
the differences in ART effectiveness between our study
and these trial findings.
Our study covered a time span of 11 years which allowed
us to evaluate ART effectiveness in two periods, namely
2000-2004 and 2005-2010. Both the crude estimates and
Table 3 Unadjusted and adjusted relative risks (95% confidence intervals) for first-line antiretroviral therapy effectiveness
at 12 and 24 months (IPEC cohort, 2000 to 2010) (Continued)
Started ART in clinical trial
No Ref. Ref. Ref. Ref.
Yes 1.10 (1.03, 1.18) 1.08 (1.01, 1.16) 1.14 (1.04, 1.25) 1.12 (1.02, 1.23)
Bold numbers indicate statistically significant results.
HIV: human immunodeficiency virus, VL: viral load, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
aGender and reported mode of HIV exposure were categorized jointly into women, men who have sex with men (MSM), heterosexual men, and injection drug
users (IDU, men and women) and other reported modes of HIV exposure (men and women). Individuals reporting both injection drug use and other modes of HIV
exposure were categorized into IDU.
bMeasurement closest to the date of start of ART up to 30 days after.
cMeasurement closest to the date of start of ART up to 7 days after.
dDefined as the presence of any Centers for Disease Control and Prevention (CDC) 1993 ADI at 90 days prior to up to 30 days after start of ART.
eChronic Hepatitis B infection was defined as persistence of a positive HBsAg for more than six months without a subsequent negative HBsAg; chronic Hepatitis C
infection was defined as a confirmed positive anti-HCV detected at least six months from the first test.
fPatients starting Integrase inhibitor-based regimens were too few and thus excluded (7 individuals with start of ART in 2010).
Table 4 Adjusted relative risks (95% confidence intervals) for first-line antiretroviral (ART) effectiveness at 12 and
24 months when assuming best-case (missing as success) and worst-case scenarios (missing as failure) (IPEC cohort,
2000 to 2010)
12 months 24 months
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Missing excluded Missing=Success Missing=Failure Missing excluded Missing=Success Missing=Failure
Age
<3 0 Ref. Ref. Ref.
30-39 1.06 (0.94, 1.19) 1.01 (0.94, 1.09) 1.15 (0.99, 1.33)
> =40 1.12 (1.00, 1.26) 1.04 (0.97, 1.13) 1.24 (1.07, 1.44)
Gender/Risk category
Women 0.90 (0.82, 0.99) 0.93 (0.87, 1.00) 0.87 (0.77, 0.98) 0.94 (0.84, 1.06) 0.94 (0.87, 1.02) 0.98 (0.84, 1.14)
Heterosexual men Ref. Ref. Ref. Ref. Ref. Ref.
MSM 1.02 (0.93, 1.12) 1.03 (0.96, 1.11) 0.98 (0.87, 1.10) 1.11 (0.98, 1.25) 1.08 (0.99, 1.17) 1.05 (0.90, 1.22)
IDU/Other 1.02 (0.89, 1.16) 1.03 (0.94, 1.14) 0.89 (0.75, 1.05) 0.95 (0.79, 1.13) 0.97 (0.87, 1.09) 0.87 (0.70, 1.09)
Education
< 4 years Ref. Ref. Ref. Ref. Ref. Ref.
4-8 years 1.07 (0.96, 1.18) 1.05 (0.97, 1.13) 1.05 (0.93, 1.20) 1.13 (0.99, 1.29) 1.06 (0.98, 1.16) 1.18 (1.00, 1.39)
> 8 years 1.13 (1.03, 1.24) 1.08 (1.01, 1.17) 1.16 (1.03, 1.30) 1.14 (1.00, 1.29) 1.07 (0.99, 1.16) 1.21 (1.03, 1.41)
Initial ART regimen
PI-based Ref. Ref. Ref.
NNRTI-based 1.17 (1.05, 1.31) 1.09 (1.02, 1.17) 1.21 (1.05, 1.39)
Calendar year of ART initiation
2005-2009 1.25 (1.15, 1.35) 1.14 (1.08, 1.22) 1.34 (1.21, 1.49) 1.14 (1.03, 1.27) 1.11 (1.03, 1.19) 1.08 (0.95, 1.23)
2000-2004 Ref. Ref. Ref. Ref. Ref. Ref.
Started ART in clinical trial
No Ref. Ref. Ref. Ref. Ref. Ref.
Yes 1.08 (1.01, 1.16) 1.05 (0.99, 1.11) 1.10 (1.00, 1.21) 1.12 (1.02, 1.23) 1.04 (0.98, 1.11) 1.24 (1.10, 1.39)
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dar period was associated with increased ART effective-
ness. This finding most likely results from the availability,
more recently, of regimens with improved drug combina-
tions, drugs with better tolerability and dosing convenience
and, as a result, improved treatment adherence [28].
We found that clinical trial participation was inde-
pendently associated with virologic suppression at 12
and 24 months from start of ART, corroborating other pub-
lished results [29,30]. Notably, in contrast to routine care,
clinical trial participants are more intensively followed, ad-
herence to study visits and drugs is monitored, drug toxic-
ities are closely sought, and access to medical appointments
is facilitated. For the time points evaluated in this study,
clinical trial participants had significantly fewer missing
viral load measurements. We believe these results highlight
the need for more vigilant monitoring within the routine
care provided by Brazil’s Unified Health System in order
to improve ART effectiveness. Additionally, a comparative
analysis of the procedures carried out in routine care ver-
sus the clinical trial setting could shed light into the most
important aspects of trial participation that lead to in-
creased ART effectiveness. Further studies are also needed
to evaluate the long-term benefits of clinical trial partici-
pation, given that at the end of the trials patients are fully
incorporated into routine care.
Two socio-demographic factors (older age and higher
education level) were found to be independently associ-
ated with increased ART effectiveness, and there was a
trend toward increased virologic suppression for one be-
havioral factor (MSM HIV risk exposure). Regarding
older age, our findings corroborate results from other
cohort studies that have found increased ART effective-
ness among older individuals [31,32]. Likewise, improved
virologic response among those with more years of for-
mal education has also been reported in studies from
both Brazil and the United States [33,34]. Older age and
higher education are likely correlated with a better un-
derstanding of the importance and value of ARTand, con-
sequently, better treatment adherence [35,36]. We also
found that MSM, compared to heterosexual men, had in-
creased ART effectiveness. In our study population, MSM
was linked to higher education, as 69% of the MSM re-
ported>8 years of formal education while only 38% of the
women and heterosexual men reported this same level of
education. In the multivariate model for the 12-month
endpoint, women were found to have decreased ART ef-
fectiveness. In other studies that considered ART dis-
c o n t i n u a t i o n sa sf a i l u r e s ,m e ns h o w e di m p r o v e dA R T
outcomes when compared to women [37]. Moreover, sev-
eral clinical trials [38] and observational studies [7,39,40]
have described a higher frequency of ART-related adverse
events among women compared to men. In our cohort,
we have previously reported that the hazard of ART
modification or discontinuation for women is 1.67 times
the hazard for men within the first year of treatment [7].
For Brazil, these findings highlight the need to focus inter-
ventions aiming to improve ART outcomes among young,
less educated heterosexual men and women, and to ad-
dress specific issues particularly among women including
ART tolerability and competing caretaking priorities.
Our study has several limitations. One is the substan-
tial fraction of missing viral load measurements. We ad-
dressed this limitation by conducting sensitivity analyses
which allowed us to generate upper and lower limits for
the ART effectiveness estimates. We also evaluated the
impact of the missing viral loads on the adjusted analysis
by modeling both best- and worst-case scenarios. These
modeling exercises generated results which are similar
to those obtained when the missing data were excluded.
In contrast, CD4 counts were not imputed and did suffer
from a somewhat smaller degree of missing data, and
therefore care is needed when extrapolating from these
results.
In summary, we have shown that in Brazil, a middle-
income country universal access to care and treatment, vi-
rologic suppression on first-line ART was achieved by
over three-quarters of patients receiving routine care in a
public facility. We also studied factors associated with vi-
rologic suppression at 12- and 24 months since ART initi-
ation and found that higher education, more recent ART
initiation and clinical trial participation were associated
with improved outcomes. To translate these findings into
applicable interventions to improve ART outcomes, the
specifics relating to the factors leading to higher virologic
suppression need to be further studied.
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